Clinical Trials Logo

Carcinoma, Non-Small-Cell Lung clinical trials

View clinical trials related to Carcinoma, Non-Small-Cell Lung.

Filter by:

NCT ID: NCT05200481 Not yet recruiting - Clinical trials for Non Small Cell Lung Cancer

Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK)

Start date: March 2022
Phase: Phase 2
Study type: Interventional

This is a phase II randomized, open-labelled, non-comparative multicenter study in which ALK+ NSCLC patients who are naïve of treatment for advanced disease will be randomized to receive brigatinib monotherapy (Arm A) or brigatinib and carboplatin-pemetrexed therapy (Arm B). An estimated 110 patients (55 in Arm A, 55 in Arm B) will be enrolled at approximately 30 centers. A safety phase will evaluate the safety of brigatinib with carboplatin and pemetrexed treatment combination (Arm B). The first twenty-six patients enrolled in Arm B will represent the population of the safety phase. Patients will be treated until they experience progressive disease, intolerable toxicity, or another discontinuation criterion is met. Continuation of brigatinib beyond progression is permitted, at the investigator's discretion, if there is evidence of continued clinical benefit. The null hypothesis is progression free survival at 12 months ≤ 69% for Arm B, which is considered not sufficiently clinically meaningful to warrant further study. The alternative hypothesis is that 86% or more of patients in Arm B would achieve progression free survival at 12 months.

NCT ID: NCT05198830 Not yet recruiting - Clinical trials for Stage IIIB Lung Cancer AJCC v8

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

Start date: June 17, 2022
Phase: Phase 2
Study type: Interventional

This phase II trial tests whether TRC102 (methoxyamine hydrochloride) in combination with pemetrexed, cisplatin, and radiation therapy works to shrink tumors in patients with stage III non-squamous non-small cell lung cancer. Chemotherapy drugs, such as TRC102, pemetrexed, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy sources to kill tumor cells and shrink tumors. Giving TRC102 in combination with pemetrexed, cisplatin, and radiation therapy may help stabilize the cancer and lengthen survival time in patients with non-small cell lung cancer.

NCT ID: NCT05198154 Not yet recruiting - Clinical trials for Advanced Lung Non-Small Cell Carcinoma

ctDNA Analysis to Monitor the Risk of Progression After First-line Immunotherapy in Patients With Advanced NSCLC

CR1STAL
Start date: January 30, 2022
Phase:
Study type: Observational [Patient Registry]

This study aims to explore the correlation of circulating tumor DNA(ctDNA) and the risk of progression in patients with advanced NSCLC who have long-term benefit from first-line immunotherapy (PFS 12 months)

NCT ID: NCT05195619 Recruiting - Clinical trials for Non-small Cell Lung Cancer

Personalized DC Vaccines in Non Small Cell Lung Cancer

Start date: December 10, 2021
Phase: Phase 1
Study type: Interventional

Phase Ib clinical trial using autologous dendritric cell (DC) vaccine loaded with personalized peptides (PEP) given in combination with low-dose cyclophosphamide, as standard of care (SOC) therapy in patients with advanced or recurrent metastatic NSCLC.

NCT ID: NCT05194072 Not yet recruiting - Clinical trials for Carcinoma, Non-Small-Cell Lung

A Study of SGN-B7H4V in Advanced Solid Tumors

Start date: January 31, 2022
Phase: Phase 1
Study type: Interventional

This study will test the safety of a drug called SGN-B7H4V in participants with solid tumors. It will also study the side effects of this drug. A side effect is anything a drug does to your body besides treating your disease. Participants will have cancer that has spread in the body near where it started (locally advanced) and cannot be removed (unresectable) or has spread through the body (metastatic). This study will have three parts. Parts A and B of the study will find out how much SGN-B7H4V should be given to participants. Part C will use the dose found in Parts A and B to find out how safe SGN-B7H4V is and if it works to treat solid tumor cancers.

NCT ID: NCT05192681 Enrolling by invitation - Clinical trials for Advanced Non-small-cell Lung Cancer

Tislelizumab as Cross-line Treatment for Advanced NSCLC

Start date: October 10, 2021
Phase: Phase 2
Study type: Interventional

This study is a single-arm, prospective, open phase II clinical study, exploring the efficacy and safety for advanced non-small cell lung cancer after progression of first-line Tislelizumab combined with chemotherapy and continuing Tislelizumab in combination with docetaxel. The primary study endpoint of this study is measured by progression-free survival (PFS). 1. Tislelizumab: The recommended dose is 200 mg/dose administered every three weeks on the first day of each cycle. 2. Docetaxel: 60-75 mg/m2 every 3 weeks, administered on day 1 of each cycle. 3. Treatment cycle: Tislelizumab in combination with docetaxel until the development of PD, unacceptable toxicities, withdrawal of informed consent, end of study, lost to follow-up, or death, whichever occurs first.

NCT ID: NCT05186974 Not yet recruiting - Clinical trials for Non-small Cell Lung Cancer

Study of Sacituzumab Govitecan-hziy Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) Without Actionable Genomic Alterations

EVOKE-02
Start date: January 2022
Phase: Phase 2
Study type: Interventional

The primary objectives of the study are to assess the objective response rate (ORR) and to determine the recommended Phase 2 dose (RP2D) of SG in combination with pembrolizumab or pembrolizumab and a platinum agent (carboplatin or cisplatin) in participants with advanced or metastatic non-small-cell lung cancer (NSCLC) without actionable genomic alterations.

NCT ID: NCT05186506 Not yet recruiting - Clinical trials for Non-Small Cell Lung Cancer

A Study Comparing Ensatinib Versus Platinum-Based Chemotherapy as Adjuvant Treatment for Stage II-IIIA ALK -Positive Non-Small Cell Lung Cancer

Start date: January 1, 2022
Phase: Phase 2
Study type: Interventional

This randomized, active-controlled, multicenter, open-label, Phase II study is designed to evaluate the efficacy and safety of ensatinib compared with Platinum-Based Chemotherapy as adjuvant treatment in ALK fusion positive II-IIIA stage non-small cell lung cancer after surgical resection

NCT ID: NCT05184712 Not yet recruiting - Clinical trials for Non-Squamous Non-small Cell Lung Cancer

Phase 3 Clinical Study of AK112 for NSCLC Patients

Start date: January 1, 2022
Phase: Phase 3
Study type: Interventional

A Randomized, Double-blind, Multi-center, Phase III Clinical Study of AK112 or Placebo Combined With Pemetrexed and Carboplatin in Patients With EGFR-mutant Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Who Have Failed to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Treatment

NCT ID: NCT05183932 Not yet recruiting - Clinical trials for Non-small Cell Lung Cancer

Surgery Versus Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer

Start date: February 28, 2022
Phase:
Study type: Observational

The development of stereotactic body radiation therapy (SBRT) for the treatment of stage I non-small cell lung cancer (NSCLC) has inspired a close partnership between thoracic surgery and radiation oncology. In this study, patients with stage I NSCLC will be screened prior to treatment and will be consented after their treatment plan has been determined. Prospectively collected patient-reported outcomes (PROs) will be collected for 3 years, as will outcomes data.